Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.80 |
| ▸ | RAB9A | P51151 | 7/20 | 0.80 |
| ▸ | NPC1 | O15118 | 6/20 | 0.80 |
| ▸ | MEN1 | O00255 | 6/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.80 |
| ▸ | TP53 | P04637 | 6/20 | 0.80 |
| ▸ | USP2 | O75604 | 6/20 | 0.80 |
| ▸ | CASP1 | P29466 | 5/20 | 0.80 |
| ▸ | CASP7 | P55210 | 5/20 | 0.80 |
| ▸ | ATM | Q13315 | 4/20 | 0.80 |
| ▸ | HBB | P68871 | 4/20 | 0.80 |
| ▸ | BRCA1 | P38398 | 4/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.80 |
| ▸ | HTT | P42858 | 3/20 | 0.80 |
| ▸ | POLB | P06746 | 2/20 | 0.80 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.80 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.80 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30349923 | 1.00 | MAPT (0.80) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL29290121 | 0.91 | MAPT (0.67) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL11938169 | 0.89 | MAPT (0.84) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL29357055 | 0.89 | MAPT (1.00) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL180716 | 0.89 | MAPT (1.00) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL29364228 | 0.89 | MAPT (1.00) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL22551263 | 0.88 | RAB9A (0.75) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL22551266 | 0.88 | MAPT (0.75) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL30349959 | 0.88 | MAPT (0.75) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL11938165 | 0.87 | MAPT (0.78) | MAPTRAB9ANPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050169837-A1 | Coumarines useful as biomarkers | NOVARTIS AG (CH) | 2005-08-04 | — | — | US | claimed |
| EP-1483262-A1 | COUMARINES USEFUL AS BIOMARKERS | Novartis AG (CH) | 2004-12-08 | — | — | EP | claimed |
| WO-2003074519-A1 | COUMARINES USEFUL AS BIOMARKERS | NOVARTIS AG (CH) | 2003-09-12 | — | — | WO | claimed |
| US-11718758-B2 | Aqueous dispersion of colored particles | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2023-08-08 | — | — | US | disclosed |
| US-20230229084-A1 | CHEMICALLY AMPLIFIED PHOTOSENSITIVE COMPOSITION, PHOTOSENSITIVE DRY FILM, PRODUCTION METHOD OF SUBSTRATE HAVING TEMPLATE FOR PLATING, AND PRODUCTION METHOD OF PLATED ARTICLE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-07-20 | — | — | US | disclosed |
| EP-3725854-B1 | COLORED PARTICLE AQUEOUS DISPERSION | MITSUBISHI PENCIL CO (JP) | 2023-07-05 | — | — | EP | disclosed |
| CN-111465662-B | Aqueous dispersion of coloured particles | 三菱铅笔株式会社 | 2023-05-26 | — | — | CN | disclosed |
| WO-2021241484-A1 | WRITING IMPLEMENT | 三菱鉛筆株式会社 | 2021-12-02 | — | — | WO | disclosed |
| US-20210071006-A1 | AQUEOUS DISPERSION OF COLORED PARTICLES | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| EP-3725854-A1 | COLORED PARTICLE AQUEOUS DISPERSION | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2020-10-21 | — | — | EP | disclosed |
| CN-111465662-A | Aqueous dispersions of pigmented particles | 三菱铅笔株式会社 | 2020-07-28 | — | — | CN | disclosed |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-30 | — | — | US | disclosed |
| EP-2797592-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013101974-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-7569337-B2 | Labeling brain tissues in vivo or in vitro; 3-Benzothiazol-2-yl-7-[4-(2-fluoro-ethyl)-piperazin-1-yl]-chromen-2-one; diagnosis, monitoring the effectiveness of a therapeutic treatment and detecting histopathological hallmarks of Alzheimer's disease | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | disclosed |
| US-20050169837-A1 | Coumarines useful as biomarkers | NOVARTIS AG (CH) | 2005-08-04 | — | — | US | disclosed |
| EP-1483262-A1 | COUMARINES USEFUL AS BIOMARKERS | Novartis AG (CH) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074519-A1 | COUMARINES USEFUL AS BIOMARKERS | NOVARTIS AG (CH) | 2003-09-12 | — | — | WO | disclosed |
| US-5550002-A | EXPOSING TO LIGHT PHOTOHARDENABLE PHOTOSENSITIVE LAYER ON LIGHT-SENSITIVE PLATE, APPLYING HEAT OR PRESSURE, REMOVING EXPOSED LAYER, EXPOSING UNEXPOSED LAYER TO HARDEN | KONICA CORPORATION (JP) | 1996-08-27 | — | — | US | disclosed |
| US-5096936-A | Acrylate-epoxy | KANSAI PAINT COMPANY, LIMITED (JP) | 1992-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050169837-A1 | Coumarines useful as biomarkers | CCNB1, CBR1, CYP1A1 | MAPT 4068/4885RAB9A 2178/4885NPC1 492/4885 |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, RBM17, RBM22 | MAPT 1125/4885RAB9A 3292/4885NPC1 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.